POSITIONED TO BEA leader in the development & production of psychedelic-based products
Our Expertise
Clinical StrategyR&D
Completion for formulation prototype and samples for clinical testing focusing on GMP quality drugs tested by qualified clinical researchers
IP StrategyMarket Products
Protect go-to-market products, with a focus on developing fast-acting drug delivery and modified release systems with proprietary formulations.
CreateShareholder Value
Invest in core capabilities and intellectual property to create a sustainable differentiated competitive position and focusing on international sales growth.
Leverage & EstablishRelationships
Relationships with healthcare practitioners, researchers and academic institutions will allow us to help support the international medical community.
Timeline
2020
Q4
2021
Q1
2021
Q2
2021
Q3
2021
Q4
2022
Q1
ABOUT USInitiative, Innovation & Integrity
Xpira will have a meaningful impact on the lives of patients suffering from serious illnesses by applying high quality proprietary therapeutic products
Xpira Pharmaceuticals Inc. (“Xpira”) was formed by leaders in the Canadian and Dutch pharmaceutical formulation development, clinical, regulatory, market access, product commercialization, and IP space. The company’s goal is to leverage its combined expertise and network to build a leading life sciences company focused on novel psychedelic-based formulation development and mushroom-based natural health products (“NHPs”).
RECOGNIZING CONSUMER CHOICETreatment and preventative therapy through innovative drug discovery and delivery.
Improving Outcomes
We have undertaken the development of controlled release dosage forms capable of improving therapeutic outcomes.
Protect our Innovations
Xpira will seek to protect its innovations and products through a multi-layered intellectual property strategy.
Balanced Value
Xpira will be sensitive to capital market movements and will act to create balanced value over the short, medium, and long term.
First Line Therapy
We will seek first line therapy status to compete with other prescription medications without the need for long term use.
Nearly 20 years of knowledge of the regulatory landscape
Recognizing Consumers
Recognizing that consumers want choice and have moved away from traditional pharmaceuticals for mental health treatments, Xpira’s focus is improve access for the “intentional use” market for treatment and preventative therapy through innovative drug discovery and delivery.